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The 26S proteasome is themajor proteolytic machine
for breaking down cytosolic and nuclear proteins in
eukaryotes. Due to the lack of a suitable assay, it is
difficult to measure routinely and quantitatively the
breakdown of proteins by the 26S proteasome
in vitro. In the present study, we developed an assay
to monitor proteasome-mediated protein degrada-
tion. Using this assay, we discovered that epidithiodi-
ketopiperazine (ETPs) blocked the degradation of our
model substrate in vitro. Further characterization re-
vealed that ETPs inhibited proteasome function by
targeting the essential proteasomal deubiquitinase
Rpn11 (POH1/PSMD14). ETPs also inhibited other
JAMM(JAB1/MPN/Mov34metalloenzyme) proteases
such asCsn5 andAMSH.An improvedETPwith fewer
non-specific effects, SOP11, stabilized a subset of
proteasome substrates in cells, induced the unfolded
protein response, and led to cell death. SOP11 repre-
sents a class of Rpn11 inhibitor and provides an alter-
native route to develop proteasome inhibitors.
INTRODUCTION
The fungus Aspergillus fumigatus is one of the most common
species to cause disease in immunocompromised individuals,
such as AIDS patients and organ transplant recipients (Dolan
et al., 2015). A. fumigatus infection causes aspergillosis and
immunosuppression (Scharf et al., 2016). The secondary metab-
olites produced by Aspergillus are considered to be important
virulence factors. Among them, gliotoxin, an epidithiodiketopi-
perazine (ETP), is the major and the most potent toxin (Scharf
et al., 2016). Most of the biological activities of gliotoxin areCell Chderived from a pair of sulfur atoms that form an unusual, intramo-
lecular disulfide bridge (Dolan et al., 2015; Scharf et al., 2016).
Gliotoxin poisons animal cells by inactivating multiple key en-
zymes through conjugation of their thiol groups. Known targets
of gliotoxin include nuclear factor kB (NF-kB), NADPH oxidase,
and glutaredoxin (Pahl et al., 1996; Srinivasan et al., 2006; Tsu-
nawaki et al., 2004). Glutathione (GSH) is important for gliotoxin
uptake andmediates its cytotoxicity in animal cells, as it reduces
gliotoxin to convert it into the toxic dithiol form (Dolan et al.,
2015). Further studies have revealed a mechanism for its inhibi-
tion involving zinc chelation: gliotoxin and other ETPs can inhibit
HIF1a interaction with p300 by ejecting the Zn2+ from p300
through the formation of a Zn2+-ETP complex (Cook et al.,
2009). This disrupts HIF1a activation and provides a plausible
molecular basis for the anti-angiogenesis effects of ETPs.
The proteasome, the major cellular machine for protein
degradation, is also reported as a target of gliotoxin (Kroll
et al., 1999). Proteasomes are essential for various cellular pro-
cesses including protein quality control, regulation of gene
expression, and cell-cycle progression. Structurally, the protea-
some is composed of a 20S core particle (CP) and 19S regulatory
particles (RPs), which cap the ends of the CP. The RP recognizes
polyubiquitinated substrates and processes them for insertion
into the CP, which contains the proteolytic active sites (Finley,
2009). There are three distinct catalytic peptidase activities iden-
tified in the CP: chymotrypsin-like, trypsin-like, and caspase-like
(Heinemeyer et al., 1997). Drugs such as bortezomib (BTZ) and
carfilzomib (CFZ), which inhibit the active sites in the CP, are
important therapeutic agents for the treatment of multiple
myeloma (Dimopoulos et al., 2015). However, patients ultimately
suffer relapse despite the clinical benefit conferred by these
drugs. Therefore, novel drugs working through different mecha-
nisms are needed. Recently, we and others discovered small-
molecule inhibitors targeting Rpn11, a JAMM protease that re-
moves polyubiquitin chains from substrate proteins (Lauinger
et al., 2017; Li et al., 2017; Perez et al., 2017). Inhibition of
Rpn11 function results in proteasome malfunction and leads toemical Biology 25, 1–9, November 15, 2018 ª 2018 Elsevier Ltd. 1
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toxin is a noncompetitive inhibitor of the chymotrypsin-like activ-
ity of the 20S proteasome (Kroll et al., 1999). However, the
detailed mechanism of this inhibition remains unknown.
Here, we developed an assay to measure the protein break-
down activity of the proteasome in purified systems and cell
extracts and identified ETPs as a scaffold for inhibiting JAMM
proteases. ETPs inhibit proteasome function by targeting the
essential proteasomal deubiquitinase Rpn11. Identification of
ETPs provides an alternative route to inhibit proteasome function
and opens the door to the development of new Rpn11 inhibitors.
RESULTS
Development of a Proteasome Substrate to Monitor
Protein Degradation In Vitro
There is no quantitative method for the simple and rapid assess-
ment of 26S proteasome protein degradation activity in vitro to
date. The Suc-LLVY-amc substrate widely used for the evalua-
tion of 20S proteasome activity does not accurately reflect pro-
tein breakdown because it only measures the chymotrypsin-like
active site of the b5 subunit. Meanwhile, it has been shown that
to block protein degradation it is necessary to inhibit both the
chymotryptic site, which is intrinsically the most sensitive to
the commonly used 20S inhibitors, as well as either the tryptic
or caspase site, which are about an order of magnitude less sen-
sitive (Demo et al., 2007; Kisselev and Goldberg, 2005). In addi-
tion, Suc-LLVY-amc is not only cleaved by the 20S proteasome
but also by other chymotrypsin-like proteases and by calpains
(Giguere and Schnellmann, 2008).
To measure protein breakdown by the proteasome, we modi-
fied an existingmethod (Kim and Huibregtse, 2009) to generate a
polyubiquitinated protein substrate, termedUbnGST-Wbp2 (WW
domain-binding protein 2, n > 30) using enzymatic approaches
(Figures 1A and S1A). Wbp2was originally isolated from amouse
embryo library. It contains an N-terminal pleckstrin homology-
glucosyltransferase (GRAM) domain and three C-terminal
PPxY motifs, which interact with multiple WW domain-contain-
ing proteins (Chen and Sudol, 1995). A previous study showed
that Wbp2 functions as a coactivator for estrogen receptor and
is closely linked to the development of breast cancer (Chen
et al., 2017). The original method described by Huibregtse and
colleagues relies on Rsp5-mediated ubiquitination of a truncated
Wbp2 (Kim and Huibregtse, 2009). We modified their method
by inserting a C-terminal hexahistidine tag into the GST-Wbp2
construct and chemically labeling the purified protein with a
cysteine-reactive fluorophore. Rsp5 assembles K63-linked ubiq-
uitin chains and contains aWWdomain that recognizes the PPxY
motifs in Wbp2. Swapping the HECT domain of Rsp5 with that
from E6AP yields a chimeric enzyme that preferentially synthe-
sizes K48-linked ubiquitin chains (Kim and Huibregtse, 2009).
The ubiquitin linkages formed on our substrate treated with the
wild-type (WT) and chimeric Rsp5 were quantified by mass
spectrometry. 87% of the linkages formed by Rsp5 were via
K63 (K63UbnGST-Wbp2), whereas 94% of those formed by the
Rsp5–E6AP chimera were via K48 (K48UbnGST-Wbp2; Table S1).
To test whether K63UbnGST-Wbp2 and K48UbnGST-Wbp2
were proteasome substrates, we incubated them with purified
human 26S proteasomes and ATP and analyzed the reactions2 Cell Chemical Biology 25, 1–9, November 15, 2018by SDS-PAGE. The fluorescence-scanned gel showed that
both proteins were degraded, consistent with the prior report
(Kim and Huibregtse, 2009). The degradation was specific and
was blocked by a Rpn11 inhibitor (capzimin [CZM]), a 20S inhib-
itor (CFZ), or a non-hydrolyzable ATP analog, AMP-PNP (Figures
1B and S1B).
To simplify and accelerate data acquisition, we adapted the
degradation assay to a format compatible with high-throughput
screening by monitoring the decrease in fluorescence polariza-
tion (FP) in a multi-well plate reader. The decreased FP indicated
that the fluorescent UbnGST-Wbp2 substrate was cleaved into
smaller species. Substrate degradation monitored in this fashion
was specific in that it was inhibited by addition of the 20S and
Rpn11 inhibitors (Figures 1C, S1C, andS1D), or the slowly hydro-
lyzable ATP analog ATPgS (Figure S1C), andwas completed by a
large excess of K48-linked Ub4 chains (Figure S1E). Note that in-
hibition of the decrease in FPby the 20S inhibitorwas not as com-
plete as with the Rpn11 inhibitor (Figure 1C), because there re-
mained some decrease in FP due to substrate deubiquitination,
which decreased its molecular weight (Figure 1B).
To test whether the FP assay could be used to measure 26S
proteasome activity directly in the cell lysate, we lysed
HEK293T cells treated with different concentrations of CFZ
and performed the assay directly in the lysate by adding
K48UbnGST-Wbp2 substrate and ATP. Ubiquitin aldehyde was
included in the assay buffer to eliminate the interference of
cysteine-based deubiquitinases (Hershko and Rose, 1987).
The IC50 for inhibition of
K48UbnGST-Wbp2 degradation by
CFZ was 110 nM, which was 20 fold higher than the IC50 ob-
tained in the Suc-LLVY-amc assay (Figure 1D). This is consistent
with the observation that inhibition of protein breakdown re-
quires blockade of at least two of the three active sites (Kisselev
and Goldberg, 2005). This assay is also compatible with lysate
prepared directly from tissue. In a recent study, we demon-
strated that overexpression of the 11S proteasome subunit
PA28a in the mouse retina does not alter ubiquitin-dependent
protein degradation (Lobanova et al., 2018). This example illus-
trates how our assay can be used to monitor 26S proteasome
activity in various disease states. It is worth noting that the
K63UbnGST-Wbp2 substrate was not suitable for use in the cell
lysate, possibly due to the presence of a high level of K63 link-
age-specific deubiquitinases (Cooper et al., 2009) (Figure S1F).
Epidithiodiketopiperazines Block Protein Degradation
Gliotoxin is the most well-known member of the family of ETP
compounds. Previous reports indicated that it functions as a
20S proteasome inhibitor targeting chymotrypsin-like activity,
and the inhibitory effect depends on an intact disulfide bond in
gliotoxin (Kroll et al., 1999). However, gliotoxin exists almost
exclusively in the dithiol form after uptake into cells due to the
reducing power of cellular glutathione (Bernardo et al., 2003).
These contradictory observations motivated us to revisit the
interaction between ETPs and the proteasome.
Taking advantage of our FP assay, we investigated the effects
of gliotoxin and its core scaffold compound, SOP6, on the
proteasome-mediated degradation of K48UbnGST-Wbp2 (Fig-
ure 2A). Both SOP6 and gliotoxin slowed down the decline
in FP, suggesting that ETP compounds inhibited proteasome
function. To test this hypothesis, we treated HCT116 cells with
AB
C
D
Figure 1. Development of an Assay to Monitor Protein Degradation
(A) Design of protein degradation assay.
(B) K48UbnGST-Wbp2 (20 nM) was incubated with 26S proteasome (5 nM) at 37C for 2 hr in the absence and presence of different inhibitors (20 mM capzimin
[CZM] or 10 mM carfilzomib [CFZ]). Reactions were fractionated by SDS-PAGE and analyzed using a Typhoon fluorescence scanner. Boxes mark the input high-
molecular-weight polyubiquitinated substrate and a deubiquitinated species that accumulated in reactions inhibited by CFZ (Verma et al., 2002).
(C) Measurement of proteasome activity using the fluorescence polarization assay. K48UbnGST-Wbp2 (2.5 nM) was incubated with 26S proteasome (1 nM) at
37C in the absence or presence of different inhibitors (10 mM CZM or 1 mM bortezomib[BTZ]).
(D) Measurement of proteasome protein breakdown activity in cell lysate in response to increasing concentrations of CFZ. Shown are the reaction kinetics (upper
panel) and dose-response (red curve in the bottom panel) of proteasome activity measured at 37C using K48UbnGST-Wbp2 as substrate and lysate from cells
treated with different concentrations of CFZ. For comparison, a dose-response curve measured using Suc-LLVY-amc is plotted in black (bottom panel). Error
bars represent SD, n = 3 wells, from 1 representative of 3 independent experiments.
See also Figure S1 and Table S1.
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Figure 2. ETPs Inhibit Protein Degradation In Vitro and in Cells
(A) SOP6 and gliotoxin block the processing of K48UbnGST-Wbp2 by the
proteasome. K48UbnGST-Wbp2 was incubated with 26S proteasome at 37C
in the absence or presence of SOP6 or gliotoxin (10 mM each).
(B) ETP treatment caused accumulation of high-molecular-weight ubiquitin
conjugates. HCT116 cells were treated for 3 hr with the indicated ETPs
(10 mM), and the cell lysates were fractionated by SDS-PAGE and immuno-
blotted with antibodies against ubiquitin.
(C) SOP6 and gliotoxin do not inhibit the chymotrypsin-like activity of the
proteasome. Suc-LLVY-amc (20 mM) was incubated with purified human 26S
proteasome (15 nM) in the absence or presence of SOP6, gliotoxin or BTZ
(20 mM each).
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tion of polyubiquitinated species. Gliotoxin and ETP analogs led
to the accumulation of ubiquitinated species, which is a
commonly used marker for proteasome inhibition (Figure 2B).
In addition, we tested ETP compounds in a UbG76V-GFP degra-
dation assay (Chou and Deshaies, 2011). The results indicated
that multiple ETP compounds blocked the degradation of pre-
accumulated UbG76V-GFP, suggesting inhibitory effects on
proteasome function (Table S2). Taken together, these results
suggested that ETPs interfered with proteasome function
in vitro and in cells. To identify the target of ETPs on the protea-
some, we first examined their effects on the chymotrypsin-like
activity of the 20S proteasome using the Suc-LLVY-amc fluores-
cence assay. Neither SOP6 nor gliotoxin showed inhibition of the
chymotrypsin-like activity, indicating that reduced ETPs did not
work as 20S proteasome inhibitors (Figure 2C). Given that glio-
toxin exists exclusively in the reduced form in cells (Bernardo
et al., 2003), it is most likely that ETPs inhibit the proteasome
through another mechanism.
ETPs Inhibit Rpn11 and Other JAMM Proteases
Chetomin is an ETP that was initially identified as a toxic second-
ary metabolite from fungi (Geiger, 1949). Interestingly, chetomin
was identified as the single positive hit in an HTS campaign for
inhibitors that target the interaction between HIF1a and its coac-
tivators p300 and CREB-binding protein (Kung et al., 2004). Sub-
sequent research revealed that ETPs block the HIF1a-p300
interaction by extracting the zinc ion from the cysteine/histi-
dine-rich domain 1 (CH1) of p300 (Cook et al., 2009).
The ubiquitin isopeptidase Rpn11 is the only essential protea-
some subunit that is known to be zinc dependent. Therefore, we
surmised that ETPs might function as proteasome inhibitors by
targeting Rpn11. To test this hypothesis, we evaluated the effect
of ETPs on JAMMdomain proteases and other metalloproteases
(Figure 3A; Tables 1 and S2). The results suggested that ETPs
specifically inhibited JAMMproteases, although the tested com-
pounds did not show selectivity between different members of
the JAMM family (Tables 1 and S2). We further confirmed that
ETPs not only inhibited Rpn11 function in the context of the intact
proteasome (Figure 3A) but also directly inhibited di-Ub cleavage
mediated by purified Rpn11,Rpn8 heterodimer (Figure 3B).
The dithiol/disulfide is required for the inhibitory effects of
ETPs against HIF1a (Cook et al., 2009). Consistent with this, dis-
rupting the disulfide bond in SOP7 completely abolished inhibi-
tory activity toward Rpn11 (Table S2). We showed previously
that compounds that inhibit Rpn11 via binding of zinc can be
counteracted by the zinc coordination compound Zn(cyclen)2+,
which titrates the inhibitor (Li et al., 2017; Perez et al., 2017).
Zn(cyclen)2+ shifted the IC50 value of SOP6 from 3.8 mM to above
100 mM, which implied that ETPs inhibited Rpn11 activity by
chelating the catalytic Zn2+ ion (Figure 3A). In addition, ZnSO4
added to cell-culture medium blunted the effect of gliotoxin on
Ub-conjugate accumulation (Figure 3C). We conclude that
ETPs inhibit proteasome function by targeting JAMM protease
Rpn11 via binding to its catalytic zinc ion.
Cellular Effects of ETPs
Gliotoxin, themost well-studied ETP, hasmultiple cellular effects
such as perturbation of microfilament structure and induction of
A C
B
Figure 3. ETPs Inhibit JAMM Domain
Proteases
(A) ETPs inhibit Rpn11 activity by binding zinc. The
IC50 for inhibition of Rpn11 activity by SOP6
was determined in the presence and absence
of a Zn(cyclen)2+ coordination complex. The Ub4-
peptide substrate was used for this assay as de-
picted. Error bars represent SD, n = 4 wells, from 1
representative of 3 independent experiments.
(B) Purified Rpn11,Rpn8 was incubated with K48-
linked di-ubiquitin in the presence of the indicated
compounds (40 mM or 10 mM), and reactions were
fractionated by SDS-PAGE and visualized with
Coomassie blue.
(C) Zn2+ counteracts gliotoxin-induced accumula-
tion of polyubiquitinated species. HCT116 cells
were treated for 3 hr with 10 mM gliotoxin or CZM in
the absence or presence of 150 mM ZnSO4 in the
culture medium, and cell lysates were fractionated
by SDS-PAGE and immunoblotted with antibodies
against ubiquitin.
See also Table S2.
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detachment was not observed upon proteasome inhibition by
either the Rpn11 inhibitor CZM or the 20S proteasome inhibitor
BTZ (Figure S2). Therefore, cell detachment is likely due to
an effect of gliotoxin on a target other than Rpn11. To testTable 1. Summary of IC50
ID Structure
IC50 (mM)
Rpn11 Csn5 AMSH
SOP6
N
N
O
O
S
S
3.8 ± 1.2 2.9 ± 0.5 2.1 ± 0.2
SOP7
N
N
O
O
S
S
>100 >100 >100
SOP10 0.7 ± 0.2 0.6 ± 0.2 1.0 ± 0.04
SOP11 1.3 ± 0.3 0.6 ± 0.2 0.9 ± 0.1
Cell Chemwhether this effect can be diminished
through medicinal chemistry optimiza-
tion, we monitored cell detachment
induced by 12 different ETPs. Among
them, SOP10 and SOP11 did not detachcells but retained inhibitory activity toward Rpn11 (Figures 2B
and 4A; Table 1). A previous study suggested that Rpn11 inhibi-
tion triggers a stress response that affects transcription
(Lauinger et al., 2017). We therefore assessed the impact of
SOP10 and SOP11 on transcription by monitoring highlyGI50 (mM)hCAII MMP-2
>100 >100 1.4 ± 0.1
>100 >100 >100
>50 >50 8.2 ± 1.0
>100 >100 4.7 ± 0.5
ical Biology 25, 1–9, November 15, 2018 5
AB
C
D
Figure 4. Cellular Effects of ETPs
(A) SOP6 and gliotoxin induce cell detachment.
Shown are microscopic images of HCT116 cells,
taken 3 hr after treatment with the indicated ETPs
(10 mM). Note that when the cells detach, as in the
top two panels, they appear more refractile and
have a tendency to clump.
(B) c-Myc mRNA expression, quantified by
qRT-PCR, in HCT116 cells harvested 4 hr post
treatment. Actinomycin D (1 mM) was included as
the positive control, and other compounds (10 mM)
were tested. Data are normalized to GAPDH.
Error bars denote mean ± SD from three inde-
pendent experiments measured in triplicate each.
*p < 0.05, **p < 0.01.
(C) HCT116 cells were treated for 6 hr with indi-
cated compounds, and cell lysates were frac-
tionated by SDS-PAGE and immunoblotted with
antibodies against NFE2L1, NFE2L2, Cul1, and
GAPDH (loading control for C and D).
(D) Same conditions as (C), except that antibodies
against XBP1, CHOP, PERK, and BiP were used.
See also Figures S2–S4.
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mRNA decreased upon treatment with these compounds, indi-
cating negative effects of ETPs on transcription (Figure 4B). Glio-
toxin was reported to inhibit the activity of HOIP, a component of
the linear ubiquitin chain assembly complex that mediates acti-
vation of IkB kinase (Sakamoto et al., 2015). We tested the effect
of ETPs on the degradation of IkB induced by tumor necrosis
factor a stimulation. Gliotoxin and chetomin strongly stabilized
IkB and SOP6 and SOP8 slightly stabilized IkB, but other ETPs
showed no effects on IkB degradation (Figure S3).
To evaluate the impact of ETPs on proteasome function in
cells in more detail, we evaluated the degradation of two endog-
enous proteasome substrates, NFE2L1 and NFE2L2. Nuclear-
factor-erythroid-derived-2-related factor 1 (NFE2L1) is an unsta-
ble transcription factor that regulates the expression of genes
that encode proteasome subunits. Upon inhibition of the protea-
some, a processed form of NFE2L1 accumulates and induces
transcription of proteasome subunit genes (Radhakrishnan
et al., 2010; Steffen et al., 2010). Multiple ETPs including
SOP10 and SOP11 mimicked CZM and induced accumulation
of processed NFE2L1 (Figure 4C). Similarly, NFE2L2, the
transcription factor that regulates antioxidant response, also
accumulated after treatment with ETPs (Figure 4C). We also
examined other endogenous proteasome substrates including
c-Myc, p53, and MDM2. ETPs showed little effect on those sub-
strates (Figure S4), which could be due to the negative impact of
those compounds on transcription (Figure 4B), weak potency in
cells, or different substrate profiles from the conventional 20S
proteasome inhibitors. Notably, the cell-detaching compounds
SOP6 and gliotoxin caused accumulation of Nedd8-conjugated6 Cell Chemical Biology 25, 1–9, November 15, 2018Cul1, whereas SOP10 and SOP11 did not
(Figure 4C). This suggests that SOP10
and SOP11 do not appreciably inhibit
the JAMM enzyme Csn5 in cells.
Previous studies revealed that Rpn11
inhibition triggered an unfolded proteinresponse (UPR) (Li et al., 2017). Surprisingly, only SOP11 pro-
voked a pronouncedUPR in cells, as determined by the accumu-
lation of phosphorylated protein kinase R-like ER kinase (PERK),
spliced X-box binding protein 1 (XBP1s), the transcription factor
CCAAT/enhancer-binding protein homologous protein (CHOP),
and binding immunoglobulin protein (BiP) (Figure 4D). Little
UPR response was triggered by SOP10, which is in agreement
with its weaker effects on the clearance of accumulated
UbG76VGFP and high GI50 (50% cell growth inhibition) on cell
proliferation (Tables 1 and S2). Based on all of the results sum-
marized above, we conclude that SOP11 is the most promising
candidate for a selective Rpn11 inhibitor among the tested ETPs.
SOP11 Blocks Cancer Cell Proliferation
Inhibition of proteasome function results in cell death, which
underlies the activity of the ‘‘omibs’’ in chemotherapy of multiple
myeloma. We and others previously showed that chemical inhi-
bition of Rpn11 blocks cancer cell proliferation (Li et al., 2017;
Song et al., 2017). We measured the effects of ETPs on the pro-
liferation of HCT116 human colon cancer cells and calculated in-
hibition of cell growth (GI50) (Tables 1 and S2). SOP6 was the
most potent growth inhibitor. However, as exemplified by its ef-
fects on cell detachment, it may work through inhibiting multiple
cellular targets in addition to Rpn11. The more selective com-
pound SOP11 inhibited cell proliferation with a GI50 value of
4.7 mM (Table 1). Of relevance to the potential for targeting
Rpn11 in ‘‘omib’’ refractory myeloma patients, we tested
SOP11 using WT and bortezomib-resistant (BTZR) retinal
pigment epithelial (RPE) cells (Wacker et al., 2012). SOP11
had the same GI50 against WT and BTZ
R RPE cells (8 mM;
AB
Figure 5. ETPs Block Cancer Cell Prolif-
eration
(A) Bortezomib-resistant cell line was not resistant
to SOP11. WT or bortezomib-resistant (BTZR)
RPE1 cells were treated with different concentra-
tions of SOP11 or BTZ for 72 hr and then mixed
with CellTiter-Glo reagent to estimate cell prolif-
eration. Measured luminescence values were
normalized to DMSO control, and data were fitted
to a dose-response equation to determine the GI50
(50% cell growth inhibition). Error bars represent
SD, n = 4 wells, from 1 representative of 3 inde-
pendent experiments. Error bars are too small to
be visualized for some data points on this graph.
(B) ETPs induce apoptosis. HCT116 cells were
treated with the indicated ETPs (10 mM) or CZM
(10 mM) for 24 hr. Western blot analyses of cell
lysates were performed with antibodies against
PARP1, gH2AX, and GAPDH, as indicated.
See also Table S2.
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worked through distinct mechanisms. In addition to inhibiting
cell growth, ETPs induced cell apoptosis, as confirmed by immu-
noblotting for caspase-cleaved poly(ADP-ribose) polymerase
(PARP1) (Figure 5B). DNA damage is a common event during
apoptosis, which is reflected by the increased phosphorylation
of H2AX (gH2AX). ETPs strongly induced H2AX phosphorylation
after 24 hr of treatment, indicating the occurrence of the DNA
damage response (Figure 5B).
DISCUSSION
Gliotoxin is the most well-studied ETP. It targets multiple pro-
teins and enzymes with important cellular functions. The protea-
some, the central cellular machine for protein degradation, has
been reported as a target of gliotoxin (Kroll et al., 1999). It inhibits
the chymotrypsin-like activity of 20S proteasome at high con-
centrations under oxidative conditions. However, gliotoxin is
rapidly reduced upon its uptake by the cell (Bernardo et al.,
2003). We report here that multiple ETPs including gliotoxin
inhibit the proteasome in vitro and in cells by targeting its essen-
tial deubiquitinase subunit Rpn11. Inhibition of Rpn11 function
by gliotoxin and other ETPs led to proteasome malfunction and
subsequent cell death. Our findings identify ETPs as an inhibitor
scaffold for targeting Rpn11 and open the door to further devel-
opment of more specific and potent Rpn11 inhibitors.
A key consideration in the characterization of inhibitors is their
target specificity. Whereas gliotoxin is one of the most potent
ETPs for inhibiting the proteasome, it is also relatively non-selec-
tive and induces morphological changes in cells that are not
observed with the selective Rpn11 inhibitor CZM (Jordan and
Pedersen, 1986). To address this non-selectivity, we surveyed aCell Chempanel of related molecules that share the
core ETP scaffold and identified SOP11
as a candidate for future studies. Unlike
gliotoxin, SOP11 did not cause the cell-
rounding phenotype. Like CZM, SOP11
triggered a UPR and induced accumula-tion of polyubiquitin conjugates and the specificproteasomesub-
stratesNFE2L1 andNFE2L2. SOP11alsomimickedCZM in that it
did not inhibit zinc-dependent enzymes unrelated to Rpn11, such
as human carbonic anhydrase and matrix metalloproteinase 2.
However, SOP11 does inhibit othermembers of the JAMM family
in vitro in addition toRpn11, includingCsn5andAMSH.However,
we did not observe effects on theCsn5 substrateCul1 at concen-
trations of SOP11 that inhibited the proteasome in cells. Thus,
SOP11 is a promising starting point to develop Rpn11 inhibitors
based on the ETP scaffold. However, considerable medicinal
chemistry optimization will be required to generate ETPs that
have sufficient potency and specificity to enable a rigorous test
of the therapeutic potential of Rpn11 inhibition.
The proteasome is the central conduit through which all sub-
strates of the ubiquitin-proteasome system (UPS) are degraded.
Genomic mutations, aneuploidy, and other alterations in cancer
cells can result in an imbalance between protein expression
and the degradative capacity of the UPS (Cenci et al., 2008; De-
shaies, 2014). This has the potential to render cancer cells more
dependent on proteasome activity than normal cells. Inhibitors
targeting the proteolytic center of the 20S proteasome, such
as BTZ, CFZ, and ixazomib, have been approved for the treat-
ment of multiple myeloma and mantle cell lymphoma, thereby
validating the hypothesis that at least some cancer cells have
heightened dependence on proteasome activity. However, pro-
teasome inhibitor therapy has not been successfully expanded
to the treatment of solid tumors, potentially due to reduced
sensitivity of solid tumor cells to proteasome inhibitors coupled
with the pharmacological properties of the existing drugs (De-
shaies, 2014). Our study provides an alternative to achieve pro-
teasome inhibition, which might translate into a therapeutic
approach in the future.ical Biology 25, 1–9, November 15, 2018 7
Please cite this article in press as: Li et al., Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11, Cell
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during aging and in neurodegenerative diseases (Saez and Vil-
chez, 2014). Proteasomedysfunction and decreased proteasome
activitymight contribute to aging-relateddiseases. For example, it
has been proposed that toxic protein aggregates that accumulate
in polyglutamine repeat diseases such as Huntington’s disease
may inhibit proteasome function (Diaz-Hernandez et al., 2006),
although this has been controversial (Hipp et al., 2012; Ortega
etal., 2007).Oneproblem inaddressing the roleofproteasomeac-
tivity in aging and disease has been a lack of suitable assays to
directlymeasure theproteinbreakdownactivityof theproteasome
in cell lysates. Consequently, these studies rely on measuring the
chymotryptic peptidase activity of the b5 subunit, which shows
poor correlation with protein breakdown activity (Bence et al.,
2001). The proteasome activity assay we developed in this study
may help to shed light on these simple yet important issues.
SIGNIFICANCE
We develop an assay to measure the protein breakdown ac-
tivity of the proteasome, and use this assay to demonstrate
that gliotoxin and other epidithiodiketopiperazines (ETPs)
inhibit proteasome activity by targeting the essential deubi-
quitinase Rpn11. These molecules quench protease activity
by chelating the active site Zn2+ ion in Rpn11. An improved
ETP, SOP11, stabilizes proteasome substrates, triggers
the unfolded protein response, and blocks proliferation of
cancer cells. Importantly it does not cause cells to round
up, an off-target effect observed with gliotoxin and other
ETPs. In addition to characterizing proteasome inhibitors
such as ETPs, our assay can be used to monitor the protein
degradation activity of the proteasome in cell lysates, which
may facilitate studies on modulation of proteasome activity
in response to disease, aging, and metabolic state.
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Antibodies
Ubiquitin Enzo Life Sciences Cat# ADI-SPA-200-F; RRID: AB_10618379
NFE2L1 Cell Signaling Cat# 8052S; RRID: AB_11178947
NFE2L2 Santa Cruz Cat# sc-365949; RRID: AB_10917561
Cul1 Bethyl Cat# A303-373A; RRID: AB_10950130
GAPDH antibody (FL-335) HRP Santa Cruz Cat# sc-25778; RRID: AB_10167668
GAPDH Cell Signaling Cat# 2118S; RRID: AB_561053
XBP1 BioLegend Cat# 647502; RRID: AB_2241743
CHOP Cell Signaling Cat# 2895P; RRID: AB_2089254
PERK Cell Signaling Cat# 5683P; RRID: AB_10841299
Bip Cell Signaling Cat# 3177P; RRID: AB_2119845
gH2AX Millipore Cat# 05-636; RRID: AB_309864
PARP1 Cell Signaling Cat# 5625S; RRID: AB_10699459
IkBa Abcam Cat# ab32518; RRID: AB_733068
c-Myc Abcam Cat# ab32072; RRID: AB_731658
MDM2 Thermo Fischer Scientific Cat# 700555; RRID: AB_2532328
P53 Abcam Cat# ab1101; RRID: AB_297667
Chemicals, Peptides, and Recombinant Proteins
Alexa Fluor 488 C5 Maleimide Thermo Fisher Scientific Cat# A10254
gliotoxin Sigma-Aldrich Cat# G9893
TNF-a Sigma-Aldrich Cat# H8916
Critical Commercial Assays
CellTiter-Glo Luminescent Cell Viability Assay Promega Cat# G7572
Experimental Models: Cell Lines
HCT116 ATCC Cat# CCL-247
UbG76V GFP Hela cell line T.F. Chou, Harbor-UCLA and LA BioMed
RPE1 WT and BTZ-resistant cell lines T.M. Kapoor, The Rockefeller University
Software and Algorithms
Graphpad Prism N/ACONTACT FOR REAGENT AND RESOURCE SHARING
Further information and request for resources and reagents should be directed and will be fulfilled by Raymond J. Deshaies
(deshaies@caltech.edu)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
HCT116 cells and RPE1 cells were grown at 37Cwith 5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal
bovine serum, penicillin-streptomycin, and 2 mM L-glutamine.
METHOD DETAILS
Plasmid Construction and Protein Purification
Purification of GST–Ube1 (E1), Rsp5 (E3 for generating K63-linked Ub chains) and Rsp5-E6AP (E3 for generating K48-linked Ub
chains) was carried out as described previously (Kim and Huibregtse, 2009). UbcH5a (E2) was purchased from Boston Biocheme1 Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018
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Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.012Inc. The plasmid encoding Wbp2-C-K222 was a kind gift from Jon M. Huibregtse. A sequence encoding ‘‘LPETGHHHHHH’’ was
inserted at the 3’ end of the Wbp2-C-K222 coding sequence through PCR reaction and the resulting construct was cloned into
the pGEX-4T1 vector resulting in the addition of an N-terminal GST tag. To purify GST–Wbp2-C-K222-His6, Rosetta cells were trans-
formed with the plasmid (RDB3386) and grown at 37C in Luria–Bertani broth containing 100 mg/mL ampicillin to an optical density of
about 0.6 at 600 nm. Then, the cells were inducedwith IPTG (final concentration 0.5mM) for three hours at 37C. After lysis of the cells
by sonication, the fusion protein was purified from the soluble franction by GSTrap High Performance column (GE healthcare life
sciences), followed by size-exclusion chromatography on a Superdex 200 prep grade column (GE healthcare life sciences).
Protein Labeling
GST–Wbp2-C-K222-His6 was covalently labeled with the fluorescent dye Alexa Fluor 488 C5 Maleimide (A10254, Thermo Fisher
Scientific) on cysteine residues by incubation with a five-fold molar excess of the dye under the conditions recommended by the
manufacturer. The reaction was quenched by the addition of 10 mM DTT. We then applied the reaction mixture to a Superdex
75HR column (GE Healthcare) to separate the free dye from the labeled protein. The concentration of the labeled protein and the
degree of labeling were determined according to the manufacturer’s instructions.
In Vitro Ubiquitination and Purification
To ubiquitinate GST–Wbp2-C-K222-His6, two separate mixtures (E3 + substrate and GST–Ube1+UbcH5a+ubiquitin+ATP) were
preincubated for two minutes and then combined to initiate the reaction. Ubiquitination was carried out at room temperature for
4 hours. The reaction mixture was purified by Ni-NTA affinity chromatography and desalting chromatography to remove E1, E2
and E3 and exchange the buffer.
Chemical Syntheses
SOP1 to SOP9 was synthesized as previously reported (Sil and Hilton, 2013). Synthetic protocols for SOP10 and SOP11 were
described below.
SOP-10
Ethyl-2-(allylamino)-2-(4-methoxybenzylthio)acetate (2).
NH2
NH
S
O
O
Me
MeO
21
Toluene, 2 hours
RT
Chemical Formula: C15H21NO3S
Molecular Weight: 295.40
Chemical Formula: C3H7N
Molecular Weight: 57.09
1) Ethyl glyoxalate
2) para-Methoxybenzyl mercaptan
Allylamine (1.90 mL, 25.2 mmol) (1) was added to a solution of ethyl glyoxalate (5.00 mL of a 50% solution in toluene, 25.2 mmol) in
toluene (30.0 mL) at room temperature (RT) and the solution stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan
(3.51 mL, 25.22 mmol) was added and the mixture stirred for 2 hours. Solvent was removed under reduced pressure and the residue
purified via Biotage Horizon (3:1, petroleum spirit 40-60C: ethyl acetate; snap 50 g) to give ethyl-2-(allylamino)-2-(4-methoxyben-
zylthio)acetate (6.00 g, 81%) (2) as a colourless oil; nmax/cm
-1 3344 (N-H), 1732 (C=O); d H (400 MHz; CDCl3) 1.27 (3H, t, J 7.1,
CH2CH3), 1.89 (1H, br s, NH), 3.11 (1H, dd, J 13.9 & 6.4, NCH2), 3.28 (1H, dd, J 13.9 & 6.6, NCH2), 3.69 (2H, s, SCH2), 3.74 (3H, s,
OCH3), 4.18 (2H, q, J 7.1, CH2CH3), 4.32 (1H, s, CHS), 5.06 – 5.10 (2H, m, CH=CH2), 5.72 – 5.77 (1H, m, CH=CH2), 6.80 (2H, d, J
8.6, Ar-H), 7.23 (2H, d, J 8.6, Ar-H); d C (101 MHz; CDCl3) 13.89 (CH2CH3), 32.85 (CH2), 47.59 (CH2), 54.99 (OCH3), 61.09 (CH2),
63.36 (CHS), 113.66 (Ar-C-H), 116.64 (CH=CH2), 129.72 (quaternary C), 129.78 (Ar-C-H), 135.07 (CH=CH2), 158.46
(quaternary C), 169.68 (CO); m/z 296 (100%, [M+H]+): Found [M+H]+ 296.1322, C15H22NO3S requires 296.1320.
2-(Allyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (3).
O
O
S
N
O
OAc
OAc
MeO
O
O
S
NH
MeO
CH2Cl2 / H2O
NaHCO3
32
Chemical Formula: C15H21NO3S
Molecular Weight: 295.40
Chemical Formula: C21H27NO8S
Molecular Weight: 453.51
Me
Me
Diacetoxyacetyl chloride
A solution of diacetoxyacetyl chloride (4.74 g, 24.4 mmol) in dichloromethane (15.0 mL) was added dropwise to a rapidly stirred
biphasic mixture of ethyl-2-(allylamino)-2-(4-methoxybenzylthio)acetate (6.00 g, 20.3 mmol) (2) and sodium hydrogen carbonateCell Chemical Biology 25, 1–9.e1–e9, November 15, 2018 e2
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layers were separated and the aqueous phase extracted with dichloromethane (2 x 100 mL). The combined organic extracts were
dried over MgSO4, filtered and solvent removed under reduced pressure to give 2-(allyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-ox-
oethyl)amino)-2-oxoethane-1,1-diyl diacetate (8.93 g, 97%) (3) as a colourless oil that did not require further purification; nmax/cm
-1
1770 (C=O), 1743 (C=O), 1681 (C=O); d H (400 MHz; CDCl3) 1.20 (3H, t, J 7.1, CH2CH3), 1.95 (3H, s, OC(O)CH3), 2.11 (3H, s, OC(O)
CH3), 3.67 (2H, s, SCH2), 3.73 (3H, s, OCH3), 3.99 (1H, dd, J 17.7 & 5.4, NCH2), 4.09 (2H, d, J 7.1, CH2CH3), 4.25 (1H, dd, J 17.7 & 5.5,
NCH2), 5.19 – 5.23 (2H, m, CH=CH2), 5.84 – 5.89 (1H, m, CH=CH2), 6.08 (1H, s, CHS), 6.80 (2H, d, J 8.6, Ar-H), 7.03 (1H, s, CH(OAc)2),
7.19 (2H, d, J 8.6, Ar-H); dC (101MHz; CDCl3) 13.70 (CH2CH3), 20.29 (C(O)CH3), 34.90 (CH2), 47.12 (CH2), 54.99 (OCH3), 60.77 (CHS),
62.08 (CH2), 83.86 (CH(OAc)2), 113.80 (Ar-C-H), 117.56 (CH=CH2), 128.48 (quaternaryC), 130.02 (Ar-C-H), 133.22 (CH=CH2), 158.73
(quaternary C), 165.41 (CO), 167.14 (CO), 168.37 (CO), 168.69 (CO);m/z 454 (100%, [M+H]+): Found [M+H]+ 454.1539, C21H28NO8S
requires 454.1536.
(±)-(3S,6S)-1,4-Diallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (4).
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Chemical Formula: C21H27NO8S
Molecular Weight: 453.51
Chemical Formula: C26H30N2O4S2
Molecular Weight: 498.66
MeCN
DMAP (MW)
3 4
1) Allylamine
2) para-Methoxybenzyl mercaptan
Allylamine (0.62 mL, 8.31 mmol) was added to a solution of 2-(allyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-oxo-
ethane-1,1-diyl diacetate (2.09 g, 4.62 mmol) (3) in acetonitrile (15.0 mL) followed by addition of para-methoxybenzyl mercaptan
(1.29 mL, 9.23 mmol) and the resulting mixture stirred for 2 minutes. DMAP (0.28 g, 2.31 mmol) was added and the mixture heated
in the microwave at 140C for 30 minutes, allowed to cool to room temperature and solvent removed under reduced pressure. The
residue was purified via Biotage Horizon (3:1, petroleum spirit 40-60C: ethyl acetate; snap 25 g) and further purified by recrystal-
lisation (petroleum spirit 40-60C: ethyl acetate) to give (±)-(3S,6S)-1,4-diallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione
(1.67 g, 72%) (4) as a colourless solid; m.p. 70-71C; nmax/cm
-1 1675 (C=O), 1609 (C=C), 1465 (CH2), 832 (C-H); d H (400 MHz,
CDCl3) 3.82 – 3.91 (12H, m, NCH2 & OCH3 & SCH2), 3.98 – 4.02 (2H, m, NCH2), 4.45 (2H, s, CHS), 4.62 – 4.68 (2H, m, CH=CH2),
4.99 – 5.05 (2H, m, CH=CH2), 5.48 – 5.54 (2H, m, CH=CH2), 6.88 – 6.90 (4H, m, Ar-H), 7.36 – 7.38 (4H, m, Ar-H); d C (101 MHz,
CDCl3) 36.74 (CH2), 45.85 (CH2), 55.56 (OCH3), 58.20 (CHS), 114.28 (CH=CH2), 119.78 (CH2), 129.04 (quaternary C), 130.91
(Ar-C-H), 130.95 (Ar-C-H), 159.36 (quaternary C), 165.09 (CO); m/z 499 (100%, [M+H]+); Found [M+H]+ 499.1723, C26H31N2O4S2
requires 499.1725.
(±)-(3S,6S)-1,3,4,6-Tetraallyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (5).
O
N
S
N
O
MeO
Chemical Formula: C32H38N2O4S2
Molecular Weight: 578.79
LiHMDS
THF, -78 °C
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Chemical Formula: C26H30N2O4S2
Molecular Weight: 498.66
OMe OMe
Allyl bromide
LiHMDS (4.14 mL of a 1M solution in tetrahydrofuran, 4.14 mmol) was added dropwise to a solution of (3S,6S)-1,4-diallyl-3,6-
bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.83 g, 1.65 mmol) (4) and allyl bromide (0.43 mL, 4.96 mmol) in tetrahydrofuran
(20.0 mL) at -78C and the resulting mixture stirred at this temperature for 1 hour and 1.5 hours at 0C. Saturated aqueous sodium
hydrogen carbonate (10.0 mL) was added and solvent removed under reduced pressure. The residue was partitioned between water
(10.0 mL) and dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 x 10.0 mL) and the combined
extracts were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue was purified via Biotage Horizon
(4:1, petroleum spirit 40-60C: ethyl acetate; snap 10 g) to give (±)-(3S,6S)-1,3,4,6-tetraallyl-3,6-bis((4-methoxybenzyl)thio)pipera-
zine-2,5-dione (0.53 g, 55%) (5) as a pale yellow oil; nmax/cm
-1 1656 (C=O), 1610 (C=C), 1001 (C-O-C), 835 (C-H); d H (400 MHz,e3 Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018
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Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.012CDCl3) 2.69 (2H, d, J 14.2, CH2CH=CH2), 3.21 (2H, d, J 14.1, CH2CH=CH2), 3.79 (6H, s, OCH3), 3.94 – 3.99 (2H, m, SCH2), 4.05 – 4.09
(2H,m, SCH2), 4.23 – 4.27 (4H,m, NCH2), 5.13 – 5.22 (2H,m, CH=CH2), 5.25 (4H, dd, J 10.2 & 1.2, CH=CH2), 5.40 (2H, dd, J 10.3 & 1.4,
CH=CH2), 5.52 – 5.63 (2H, m, CH=CH2), 6.02 – 6.07 (2H, m, CH=CH2), 6.81 – 6.85 (4H, m, Ar-H), 7.20 – 7.24 (4H, m, Ar-H); d C (101
MHz, CDCl3) 35.66 (CH2), 41.66 (CH2), 47.69 (CH2), 55.42 (OCH3), 73.15 (quaternary C), 114.20 (CH=CH2), 118.63 (CH2), 121.15
(CH2), 128.06 (quaternary C), 130.53 (CH=CH2), 131.28 (Ar-C-H), 133.62 (Ar-C-H), 159.05 (quaternary C), 164.94 (CO); m/z 601
(100%, [M+Na]+); Found [M+Na]+ 601.2176, C32H38N2O4S2Na requires 601.2170.
(±)-(1S,4S)-1,2,4,5-Tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (6).
BBr3, CH2Cl2
-78 °C to RT,
I2
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Chemical Formula: C16H20N2O2S2
Molecular Weight: 336.47
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Chemical Formula: C32H38N2O4S2
Molecular Weight: 578.79
Boron tribromide (0.14 mL, 1.50 mmol) was added dropwise to a solution of 1,3,4,6-tetraallyl-3,6-bis((4-methoxybenzyl)thio)piper-
azine-2,5-dione (0.44 g, 0.75mmol) (5) in dichloromethane (20.0mL) at -78C. The resultingmixture was stirred for 15minutes where-
upon Rochelle’s salt (20.0 mL of a saturated aqueous solution) was added and the biphasic mixture stirred for 15 minutes until the
yellow colour had dissipated. The resulting mixture was stirred at room temperature for 10 minutes, whereupon iodine was added
portionwise until the colour due to iodine just persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added
and the mixture stirred for 10 minutes, diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated
and the aqueous phase extracted with dichloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4,
filtered and solvent removed under reduced pressure. The residue was purified via Biotage Horizon (4:1, petroleum spirit
40-60C: ethyl acetate; snap 10 g) and further purified by recrystallisation (petroleum spirit 40-60C: ethyl acetate) to give
(±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.10 g, 41%) (6) as a colourless solid;
m.p. 180-182C; nmax/cm
-1 1639 (C=O, C=C), 1462 (CH2), 749 (CH2); d H (400 MHz, CDCl3) 3.20 – 3.27 (2H, m, CH2CH=CH),
3.28 – 3.36 (2H, m, CH2CH=CH), 4.04 (2H, dd, J 16.4 & 6.8, NCH2), 4.62 (2H, dd, J 16.2 & 4.8, NCH2), 5.21 – 5.41 (8H, m,
CH=CH2), 5.89 – 5.94 (2H, m, CH=CH2), 6.12 – 6.17 (2H, m, CH=CH2); d C (101 MHz, CDCl3) 36.44 (CH2), 45.46 (CH2), 74.50
(quaternary C), 118.31 (CH=CH2), 120.60 (CH=CH2), 131.74 (CH=CH2), 132.01 (CH=CH2), 165.02 (CO); m/z 337 (100%, [M+H]
+);
Found [M+H]+ 337.1456, C16H21N2O2S2 requires 337.1448.
(±)-(6aS,12aS)-7,10-Dihydro-6a,12a-epithiodipyrido[1,2-a:1’,2’-d] pyrazine-6,12(1H,4H)-dione 13-sulfide (SOP-10).
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Chemical Formula: C16H20N2O2S2
Molecular Weight: 336.47
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Chemical Formula: C12H12N2O2S2
Molecular Weight: 280.37
S2
O
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Me
Method A
A solution of (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.04 g, 0.12 mmol) (6) in di-
chloromethane (2.00 mL) was degassed and taken under nitrogen atmosphere. To this (1,3-bis-(2,4,6-trimethylphenyl)-2-imidazoli-
dinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium (Grubbs-Hoveyda second-generation catalyst) (0.01 g, 0.01 mmol)Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018 e4
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reduced pressure. The residue was purified via Biotage Horizon (4:1, petroleum spirit 40-60C: ethyl acetate; pipette column)
and further purified by recrystallisation (petroleum spirit 40-60C: ethyl acetate) to give (±)-(6aS,12aS)-7,10-dihydro-6a,12a-epithio-
dipyrido[1,2-a:1’,2’-d]pyrazine-6,12(1H,4H)-dione 13-sulfide (0.01 g, 39%) (SOP-10) as a colourless solid; m.p. 135-137C; nmax/cm
-
1 1683 (C=O, C=C), 1351 (C-H), 1321 (C-H); d H (400 MHz, CDCl3) 2.60 – 2.72 (2H, m, CH2CH=CH), 3.29 – 3.40 (2H, m, CH2CH=CH),
3.87 – 4.08 (4H, m, NCH2), 5.86 – 5.97 (4H, m, CH=CH); d C (101 MHz, CDCl3) 28.60 (CH2), 42.30 (CH2), 70.29 (quaternary C), 121.14
(CH=CH), 122.32 (CH=CH), 165.15 (CO);m/z 303 (100%, [M+Na]+); Found [M+Na]+ 303.0253, C12H12N2O2S2Na requires 303.0238.
Method B
A solution of (±)-(1S,4S)-1,2,4,5-tetraallyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.04 g, 0.13 mmol) (6) in di-
chloromethane (2.00 mL) was degassed and taken under nitrogen atmosphere. To this (1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidi-
nylidene)dichloro (phenylmethylene)(tricyclohexylphosphine)ruthenium (Grubbs second-generation catalyst) (0.01 g, 0.01mmol) was
added and the resulting mixture heated at 80C for 30 minutes in the microwave, cooled to RT and solvent removed under reduced
pressure. The residue was purified via Biotage Horizon (4:1, petroleum spirit 40-60C: ethyl acetate; snap 5 g) and further purified
by recrystallisation (petroleum spirit 40-60C: ethyl acetate) to give (±)-(6aS,12aS)-7,10-dihydro-6a,12a-epithiodipyrido[1,2-a:1’,2’-
d]pyrazine-6,12(1H,4H)-dione 13-sulfide (0.01 g, 7%) (SOP-10) as a colourless solid; identical spectroscopic data to that obtained
previously for (SOP-10).
SOP-11
Ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate (8).
NH2
NH
O
O Me
S
MeO
PhToluene, 2 hours
RT
87
Chemical Formula: C7H9N
Molecular Weight: 107.15
Chemical Formula: C19H23NO3S
Molecular Weight: 345.46
1) Ethyl glyoxalate
2) para-Methoxybenzyl mercaptan
Benzylamine (2.76 mL, 25.2 mmol) (7) was added to a solution of ethyl glyoxalate (5.00 mL of a 50% solution in toluene, 25.2 mmol)
in toluene (20.0 mL) at room temperature (RT) and stirred for 2 minutes, whereupon para-methoxybenzyl mercaptan (3.54 mL,
25.2 mmol) was added and the mixture stirred for 2 hours. Solvent was removed under reduced pressure and the residue purified
via Biotage Horizon (3:1, petroleum spirit 40-60C: ethyl acetate; snap 50 g) to give ethyl-2-(benzylamino)-2-((4-methoxybenzyl)
thio)acetate (7.56 g, 87%) (8) as a colourless oil; nmax/cm
-1 3347 (N-H), 1732 (C=O); d H (400 MHz; CDCl3) 1.31 (3H, t, J 7.2,
CO2CH2CH3), 1.88 (1H, br s, NH), 3.72 (1H, d, J 13.1, SCH2), 3.75 – 3.77 (2H, m, NHCH2), 3.79 (3H, s, OCH3), 3.87 (1H, d, J 13.1,
SCH2), 4.22 (2H, q, J 7.2, CO2CH2CH3), 4.35 (1H, s, CH), 6.84 (2H, d, J 8.7, Ar-H), 7.23 – 7.29 (7H, m, Ar-H); d C (101 MHz;
CDCl3) 14.15 (CO2CH2CH3), 33.23 (SCH2), 49.22 (NHCH2), 55.28 (OCH3), 61.41 (CO2CH2CH3), 63.71 (CH), 114.00 (Ar-C-H),
127.19 (Ar-C-H), 128.41 (Ar-C-H), 128.48 (Ar-C-H), 130.07 (Ar-C-H), 138.79 (quaternary C), 158.76 (quaternary C), 169.97
(CO2CH2CH3); m/z 346 (100%, [M+H]
+): Found [M+H]+ 346.1477, C19H24NO3S requires 346.1482.
2-(Benzyl(2-ethoxy-1-(4-methoxybenzylthio)-2-oxoethyl)amino)-2-oxoethane-1,1-diyl diacetate (9).
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Chemical Formula: C19H23NO3S
Molecular Weight: 345.46
Chemical Formula: C25H29NO8S
Molecular Weight: 503.56
CH2Cl2 / H2O
NaHCO3
Diacetoxyacetyl chloride
A solution of diacetoxyacetyl chloride (5.11 g, 26.3 mmol) in dichloromethane (20.0 mL) was added dropwise to a rapidly stirred
biphasic mixture of ethyl-2-(benzylamino)-2-((4-methoxybenzyl)thio)acetate (7.56 g, 21.9 mmol) (8) and sodium hydrogen carbonate
(12.9 g, 153 mmol) in dichloromethane (150 mL) and water (100 mL) at RT and the resulting mixture stirred rapidly for 12 hours. The
layers were separated and the aqueous phase extracted with dichloromethane (2 x 100 mL). The combined extracts were dried over
MgSO4, filtered and solvent removed under reduced pressure to give 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)
amino)-2-oxoethane-1,1-diyl diacetate (10.5 g, 95%) (9) as a colourless oil that did not require further purification; nmax/cm
-1 1770
(C=O), 1739 (C=O), 1685 (C=O); d H (400 MHz; CDCl3) 1.15 (3H, t, J 7.1, CH2CH3), 1.95 (3H, s, OC(O)CH3), 1.98 (3H, s, OC(O)e5 Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018
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Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.012CH3), 3.72 (2H, s, SCH2), 3.75 (3H, s, OCH3), 3.98 – 4.02 (2H, m, CH2CH3), 4.59 (1H, d, J 17.4, NCH2), 4.86 (1H, d, J 17.4, NCH2), 5.85
(1H, s, CHS), 6.79 (2H, d, J 8.4, Ar-H), 6.92 (1H, s, CH(OAc)2), 7.16 – 7.27 (7H, m, Ar-H); d C (101 MHz; CDCl3) 13.76 (CH2CH3), 20.20
(C(O)CH3), 20.25 (C(O)CH3), 35.49 (CH2), 48.68 (CH2), 55.18 (OCH3), 61.65 (CHS), 62.21 (CH2CH3), 83.99 (CH(OAc)2), 113.97 (Ar-C-
H), 126.79 (Ar-C-H), 127.66 (Ar-C-H), 128.48 (Ar-C-H), 128.65 (quaternary C), 130.21 (Ar-C-H), 135.72 (quaternary C), 158.87
(quaternary C), 165.76 (CO), 167.16 (CO), 168.34 (CO), 168.62 (CO); m/z 504 (100%, [M+H]+): Found [M+H]+ 504.1688,
C25H30NO8S requires 504.1692.
1,4-Dibenzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione (10).
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Chemical Formula: C25H29NO8S
Molecular Weight: 503.56
Chemical Formula: C27H28N2O4S
Molecular Weight: 476.59
MeOH, DMAP
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Benzylamine
Benzylamine (0.21 mL, 1.93 mmol) was added to a solution of 2-(benzyl(2-ethoxy-1-((4-methoxybenzyl)thio)-2-oxoethyl)amino)-2-
oxoethane-1,1-diyl diacetate (0.65 g, 1.29 mmol) (9) in methanol (15.0 mL) and the resulting mixture stirred for 2 minutes. DMAP
(0.08 g, 0.64 mmol) was added and the resulting mixture stirred for 5 hours at RT and solvent removed under reduced pressure.
The residue was purified via BiotageHorizon (3:1, petroleum spirit 40-60C: ethyl acetate; snap 25 g) and further purified by recrys-
tallisation (petroleum spirit 40-60C: ethyl acetate) to give 1,4-dibenzyl-3-methoxy-6-((4-methoxybenzyl)thio)piperazine-2,5-dione
(0.49 g, 79%) (10) as a colourless solid; m.p. 85-88C; nmax/cm
-1 3030 (C-H), 3005 (C-H), 1671 (C=O), 1357 (CH3), 1002 (C-O-C),
832 (C-H); d H (400 MHz, CDCl3) 3.53 (3H, s, OCH3), 3.62 (1H, d, J 14.5, NCH2), 3.87 – 3.90 (4H, m, SCH2 & OCH3), 4.09 (1H, d, J
13.8, SCH2), 4.25 (1H, d, J 14.9, NCH2), 4.66 (1H, s, CHO), 4.45 (1H, s, CHS), 5.18 (2H, d, J 14.7, NCH2), 6.91 – 6.95 (2H, m,
Ar-H), 7.16 – 7.29 (6H, m, Ar-H), 7.36 (6H, dd, J 16.4 & 9.2, Ar-H); d C (101 MHz, CDCl3) 36.29 (CH2), 45.93 (CH2), 48.07 (CH2),
55.39 (OCH3), 57.66 (OCH3), 85.50 (CHS), 114.29 (CHO), 128.03 (Ar-C-H), 128.19 (Ar-C-H), 128.53 (Ar-C-H), 128.66 (Ar-C-H),
128.75 (Ar-C-H), 129.01 (Ar-C-H), 130.88 (Ar-C-H), 134.98 (quaternary C), 135.30 (quaternary C), 159.27 (quaternary C), 162.73
(CO), 166.29 (CO); m/z 477 (100%, [M+H]+); Found [M+H]+ 477.1841, C27H29N2O4S requires 477.1848.
1,3,4-Tribenzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione (11).
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Chemical Formula: C34H34N2O4S
Molecular Weight: 566.71
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Chemical Formula: C27H28N2O4S
Molecular Weight: 476.59
LiHMDS
THF, -78 °C
Benzyl bromide
LiHMDS (0.50 mL of a 1M solution in tetrahydrofuran, 0.50 mmol) was added dropwise to a solution of 1,4-dibenzyl-3-methoxy-6-
((4-methoxybenzyl)thio)piperazine-2,5-dione (0.20 g, 0.41 mmol) (10) and benzyl bromide (0.05 mL, 0.41 mmol) in tetrahydrofuran
(2.00 mL) at -78C and the resulting mixture stirred at this temperature for 1.5 hours and 1 hour at 0C. Saturated aqueous sodium
hydrogen carbonate (10.0 mL) was added and solvent removed under reduced pressure. The residue was partitioned between water
(10.0 mL) and dichloromethane (20.0 mL). The aqueous phase was extracted with dichloromethane (2 x 10.0 mL) and the combined
extracts were dried (MgSO4), filtered and solvent removed under reduced pressure. The residue was purified via Biotage Horizon
(3:1, petroleum spirit 40-60C: ethyl acetate; snap 10 g) to give 1,3,4-tribenzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-
dione (0.14 g, 59%) (11) as a pale yellow oil; nmax/cm
-1 3004 (C-H), 1670 (C=O), 1453 (CH2), 1357 (CH3), 1000 (C-O-C); d H (400 MHz,
CDCl3) 3.18 (1H, d, J 10.9, CH2), 3.32 (1H, d, J 14.2, CH2), 3.38 (1H, d, J 8.8, SCH2), 3.44 (3H, s, OCH3), 3.73 (1H, d, J 9.1, SCH2), 3.78
(3H, s, OCH3), 4.05 (1H, d, J 14.2, NCH2), 4.13 (1H, s, CHO), 4.65 (1H, d, J 14.7, NCH2), 4.75 (1H, d, J 14.7, NCH2), 5.30 (1H, d, J 14.7,
NCH2), 7.01 (6H, dd, J 11.5 & 4.5, Ar-H), 7.14 – 7.17 (3H, m, Ar-H), 7.29 – 7.33 (8H, m, Ar-H), 7.54 – 7.57 (2H, m, Ar-H); d C (101 MHz,
CDCl3) 34.61 (CH2), 43.51 (CH2), 47.21 (CH2), 47.91 (CH2), 55.41 (OCH3), 82.93 (OCH3), 113.98 (CHO), 127.63 (Ar-C-H), 128.13
(Ar-C-H), 128.36 (Ar-C-H), 128.60 (Ar-C-H), 128.82 (Ar-C-H), 129.03 (Ar-C-H), 129.39 (Ar-C-H), 129.56 (Ar-C-H), 130.19 (Ar-C-H),
130.48 (Ar-C-H), 130.65 (Ar-C-H), 133.87 (quaternary C), 134.70 (quaternary C), 135.44 (quaternary C), 137.89 (quaternary C),
159.02 (quaternary C), 164.23 (quaternary C), 165.06 (CO), 166.07 (CO); m/z 589 (100%, [M+Na]+); Found [M+Na]+ 589.2107,
C34H34N2O4SNa requires 589.2137.Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018 e6
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Molecular Weight: 566.71
TFA, CH2Cl2
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para-Methoxybenzyl mercaptan
TFA (1.00 mL, 13.0 mmol) was added to a solution of 1,3,4-tribenzyl-6-methoxy-3-((4-methoxybenzyl)thio)piperazine-2,5-dione
(0.18 g, 0.32 mmol) (11) in dichloromethane (5.00 mL) at RT followed by the addition of para-methoxybenzyl mercaptan (0.13 mL,
0.95 mmol) and the resulting mixture stirred at this temperature for 18 hours. After, the solution was diluted in dichloromethane
(10.0 mL) and washed with saturated aqueous sodium hydrogen carbonate (10.0 mL). The aqueous phase was extracted with di-
chloromethane (2 x 10.0 mL) and the combined extracts were dried (MgSO4), filtered and solvent removed under reduced pressure.
The residue was purified via Biotage Horizon (4:1, petroleum spirit 40-60C: ethyl acetate; snap 10 g) to give (±)-(3S,6S)-1,3,4-tri-
benzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.20 g, 91%) (12) as a pale yellow oil; nmax/cm
-1 3032 (C-H), 3005 (C-H),
1666 (C=O), 1356 (CH3), 1001 (C-O-C), 833 (C-H), 730 (C-H); d H (400 MHz, CDCl3) 3.77 – 3.78 (2H, m, CH2), 3.79 (3H, s, OCH3), 3.84
(3H, s, OCH3), 3.87 – 3.89 (4H,m, SCH2 &NCH2), 3.97 – 4.06 (2H,m, SCH2), 4.27 (1H, s, CHS), 4.62 (1H, d, J 15.1, NCH2), 5.28 (1H, d, J
15.1, NCH2), 6.51 – 6.54 (3H,m, Ar-H), 6.75 – 6.81 (4H,m, Ar-H), 6.84 – 6.88 (4H,m, Ar-H), 7.00 – 7.05 (4H,m, Ar-H), 7.13 – 7.20 (4H,m,
Ar-H), 7.27 – 7.31 (2H, m, Ar-H), 7.59 – 7.63 (2H, m, Ar-H); d C (101 MHz, CDCl3) 35.31 (CH2), 36.93 (CH2), 43.44 (CH2), 46.98 (CH2),
47.70 (CH2), 55.38 (OCH3), 58.20 (OCH3), 75.78 (quaternary C), 113.96 (CHS), 127.84 (Ar-C-H), 128.50 (Ar-C-H), 128.58 (Ar-C-H),
128.62 (Ar-C-H), 128.81 (Ar-C-H), 128.90 (Ar-C-H), 129.17 (Ar-C-H), 129.86 (Ar-C-H), 130.35 (Ar-C-H), 130.65 (Ar-C-H), 130.74
(Ar-C-H), 130.81 (Ar-C-H), 130.96 (Ar-C-H), 133.96 (quaternary C), 134.27 (quaternary C), 134.41 (quaternary C), 135.74 (quaternary
C), 137.79 (quaternary C), 158.96 (quaternary C), 159.17 (quaternary C), 163.98 (CO), 165.99 (CO);m/z 711 (100%, [M+Na]+); Found
[M+Na]+ 711.2355, C41H40N2O4S2Na requires 711.2327.
(±)-(1S,4S)-1,2,5-Tribenzyl-7-thia-2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (SOP-11).
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Molecular Weight: 446.58
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Boron tribromide (0.70 mL of a 1M solution in dichloromethane, 0.70 mmol) was added dropwise to a solution of (±)-(3S,6S)-1,3,4-
tribenzyl-3,6-bis((4-methoxybenzyl)thio)piperazine-2,5-dione (0.12 g, 0.17 mmol) (12) in dichloromethane (2.00 mL) at -78C. The re-
sultingmixture was stirred for 15minutes whereupon aqueous sodium hydrogen carbonate (10.0mL of a saturated aqueous solution)
and methanol (1.00 mL) were added and the biphasic mixture stirred for 15 minutes until the yellow colour had dissipated. The re-
sulting mixture was stirred at room temperature for 10 minutes, whereupon iodine was added portionwise until the colour due to
iodine just persisted and stirring was maintained for 2 minutes. Sodium thiosulfate was added and the mixture stirred for 10 minutes,
diluted with dichloromethane (10.0 mL) and water (20.0 mL). The layers were separated and the aqueous phase extracted with di-
chloromethane (2 x 20.0 mL). The combined organic extracts were dried over MgSO4, filtered and solvent removed under reduced
pressure. The residue was purified via Biotage Horizon (3:1, petroleum spirit 40-60C: ethyl acetate; snap 10 g), followed by HPLC
separation and further purified by recrystallisation (petroleum spirit 40-60C: ethyl acetate) to give (±)-(1S,4S)-1,2,5-tribenzyl-7-thia-
2,5-diazabicyclo[2.2.1]heptane-3,6-dione 7-sulfide (0.04 g, 50%) (SOP-11) as a colourless solid; m.p. 122-124C; nmax/cm
-1 1641
(C=O), 1438 (CH2), 749 (C-H); d H (400 MHz; CDCl3) 3.62 – 3.68 (1H, m, CH2), 3.73 – 3.79 (1H, m, CH2), 4.23 (1H, d, J 15.2,
NCH2), 4.34 (1H, d, J 15.0, NCH2), 4.86 (1H, d, J 14.9, NCH2), 5.12 (1H, d, J 15.0, NCH2), 5.26 (1H, s, CHS), 7.12 – 7.24 (15H, m,
Ar-H); d C (101 MHz; CDCl3) 36.39 (CH2), 46.11 (CH2), 48.78 (CH2), 64.13 (CHS), 76.53 (quaternary C), 127.38 (Ar-C-H), 127.98
(Ar-C-H), 128.17 (Ar-C-H), 128.68 (Ar-C-H), 128.74 (Ar-C-H), 128.80 (Ar-C-H), 128.98 (Ar-C-H), 129.40 (Ar-C-H), 130.42 (Ar-C-H),
133.96 (quaternary C), 134.54 (quaternary C), 136.00 (quaternary C), 164.83 (CO), 165.31 (CO); m/z 469 (100%, [M+Na]+): Found
[M+Na]+ 469.1097, C25H22N2O2S2Na requires 469.1101.e7 Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018
Please cite this article in press as: Li et al., Epidithiodiketopiperazines Inhibit Protein Degradation by Targeting Proteasome Deubiquitinase Rpn11, Cell
Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.012SDS-PAGE Analysis of Proteasome Activity
20 nM UbnGST–Wbp2 and 4 nM purified human 26S proteasome were incubated at 37C for 2 hours in the presence of different
compounds plus 1 mM ATP. The reactions were stopped with 23 SDS sample buffer and analyzed by SDS–PAGE. The gel was
scanned using Typhoon FLA 9500 biomolecular imager (GE Healthcare life sciences) with filter for fluorophore Alexa 488.
Fluorescence Polarization Assay
The fluorescence polarization assay was performed in a low-volume 384-well solid black plate to which the components were added
in the following sequence: 1) 5 ml compound in 3% (v/v) DMSO or 3% DMSO control, 2) 5 ml of 26S proteasome (Enzo life science),
3) 5 ml of 5 nM UbnGST–Wbp2 to initiate the reaction. Fluorescence polarization wasmeasured using a plate reader with excitation at
480 nm and emission at 520 nm (PHERAstar, BMG Labtech).
Evaluation of Ubiquitin Linkage
Substrate samples were fractionated on an SDS-polyacrylamide gel and digested in-gel with trypsin. Di-Ubs of all 7 linkages (Boston
Biotech) were used to quantify the standard heavy Ub linkages. The standard heavy Ub linkages were subsequently used as internal
standards to quantify the linkages in substrates ubiquitinated by Rsp5-WT or Rsp5-E6AP. Mass spectrometry was carried out on a
Thermo Orbitrap Velos.
Rpn11,Rpn8 di-Ub Cleavage Assay
Di-ubiquitin cleavage assay was performed in 40 mMHEPES, pH7.5, 100mMNaCl, 100mMKCl and 5% (v/v) glycerol. Rpn11,Rpn8
dimer (5 mM)was incubatedwith di-UbK48 and different concentrations of inhibitors at 30C. The reactionswere stoppedwith 23SDS
sample buffer after 2 hours and analyzed by SDS–PAGE.
hCAII Assays
hCAII was expressed and purified as previously reported (Martin et al., 2013). Human carbonic anhydrase II (hCAII) assays were car-
ried out in clear Costar 96-well plates. Each well contained a volume of 100 mL including buffer (50mMHEPES buffer, pH 8.0), protein
(10 nMhCAII), inhibitor (100 mM), and substrate p-nitrophenyl acetate (500 mM). The protein and inhibitor were incubated in solution at
30C for 10 min prior to the addition of the p-nitrophenyl acetate to initiate the reaction. The change in absorbance was monitored at
405 nm for 15 min. The negative control wells, containing no inhibitor, were arbitrarily set as 100% activity. Readings from back-
ground wells, which did not contain protein, were subtracted from the active assay wells to account for background hydrolysis ac-
tivity caused by the buffer. The assays were performed in triplicate. The data were normalized to values measured for uninhibited
enzyme. Assay data are reported as the mean±standard deviation.
MMP-2 Assays
MMP-2 and OmniMMP fluorogenic substrate were purchased from Enzo Life Sciences. The assays were carried out in black NUNC
96-well plates. Each well contained a volume of 100 mL including buffer (50 mM HEPES, 10 mM CaCl2, 0.05% (v/v) Brij-35, pH 7.5),
human recombinant MMP (1.16 UMMP-2, Enzo Life Sciences), inhibitor (100 mM), fluorogenic OmniMMP substrate (4 mMMca-Pro-
Leu-Gly-Leu-Dpa-Ala-Arg-NH2$AcOH, Enzo Life Sciences). The mixture of protein and inhibitor was pre-incubated in solution at
37C for 30 min, followed by the addition of the substrate to initiate the reaction. The change in fluorescence was monitored for
30 min by BioTek synergy HT fluorescence plate readers with excitation and emission wavelengths at 320 and 400 nm, respectively.
The control wells, containing no inhibitor, were arbitrarily set as 100% activity. MMP activity was defined as the ratio of fluorescence
increase in the inhibitor wells relative to the negative control wells, expressed as a percentage. The assays were performed in trip-
licate. The data were normalized to values measured for uninhibited enzyme. Assay data are reported as the mean±standard
deviation.
UbG76V-GFP Degradation Assay
A stable HeLa cell line with the ubiquitin fusion degradation reporter UbG76V-GFP were seeded on 384-well plates (5000 cells/well)
and grown for 18 hours. Cells were treatedwithmodified DMEM (without phenol red, folic acid, riboflavin, and vitamin B12) containing
MG132 (4 mM) for 1 hour and washed twice with pre-warmed PBS. Modified DMEM containing FBS (2.5%), cycloheximide (CHX)
(50 mM), and DMSO or a test compound (0.1, 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25 and 50 mM) was added to each well. Plates
were imaged on the ImageXpress Micro microscope (Molecular Devices) after 60 to 240 min.
IkBa Degradation Assay
Hela cells were pre-treated with DMSO or compounds as indicated for 10 minutes and then treated with 25 ng/mL of recombinant
human TNF-a (Promega) for 30 minutes. Cells were lysed with RIPA buffer with protease inhibitor cocktail, fractionated by SDS–
PAGE and immunoblotted with antibodies against IkBa or GAPDH.
Quantitative Real-Time PCR of HCT116 Cell RNA
Cells were seeded in 6-well plates at 53105 cells/well in DMEMmedium for 16 hours before drug treatment. Compoundswere added
at 10 mM each except for actinomycin D, which was used at 1 mM as a positive control. RNA was isolated using RNeasy kit (Qiagen).Cell Chemical Biology 25, 1–9.e1–e9, November 15, 2018 e8
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Chemical Biology (2018), https://doi.org/10.1016/j.chembiol.2018.07.012cDNA was synthesized with QuantiTect Reverse Transcription Kit (Qiagen). Quantitative real-time PCR was performed using Roche
Lightcycler 480 and SYBR green I master kit. Sequences of primers used for qRT-PCR were as follows: c-Myc: Fwd, 5’-caccagcagc
gactctga; Rev, 5’-gatccagactctgaccttttgc; GAPDH: Fwd, 5’-acccactcctccacctttgac; Rev, 5’-ctgttgctgtagccaaattcgt.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphpad Prism 7 was used for statistical analysis of the data from proteasome activity assays, Rpn11 activity assays, cell viability
assays and quantitative real-time PCR. For each analysis, total n and S.D. are presented in the figure legend. Data were fitted
to a dose-response equation (three parameters) to determine the IC50 or GI50. Quantitative real-time PCR data were analyzed by
Student’s t test (two-tailed). Differences were statistically significant when P<0.05.
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